Priya Rastogi
Impact in
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
Papers in
-
- Breast Cancer Treatment Studies 44
- Oncology 61
- HER2/EGFR in Cancer Research 37
- Cancer Treatment and Pharmacology 14
- PARP inhibition in cancer therapy 6
- Cancer Risks and Factors 5
- Co-authors
- Charles Edward Geyer Jr (40 shared papers)Norman Wolmark (40 shared papers)Eleftherios P. Mamounas (34 shared papers)Sandra M. Swain (26 shared papers)Victor G. Vogel (8 shared papers)André Robidoux (15 shared papers)Louis Fehrenbacher (21 shared papers)Soonmyung Paik (16 shared papers)
- Journals
- Journal of Clinical Oncology (22 papers)Annals of Oncology (17 papers)JNCI Journal of the National Cancer Institute (8 papers)Breast Cancer Research and Treatment (8 papers)The Lancet Oncology (6 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Priya Rastogi
112 papers receiving 16.1k citations
Priya Rastogi's Hit Papers
Peers
Comparison fields: 5 of 125
- Cancer Research 7.1k
- Oncology 7.8k
- Pulmonary and Respiratory Medicine 2.8k
- Radiology, Nuclear Medicine and Imaging 1.8k
- Pathology and Forensic Medicine 1.2k
Countries citing papers authored by Priya Rastogi
This map shows the geographic impact of Priya Rastogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priya Rastogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priya Rastogi more than expected).
Fields of papers citing papers by Priya Rastogi
This network shows the impact of papers produced by Priya Rastogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priya Rastogi. The network helps show where Priya Rastogi may publish in the future.
Co-authors
The 25 scholars most cited alongside Priya Rastogi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 114 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Hit paper breakdown → | 2014 | 3645 |
| 2 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Hit paper breakdown → | 2018 | 1980 |
| 3 | Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 Hit paper breakdown → | 2008 | 1442 |
| 4 | Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer Hit paper breakdown → | 2021 | 1164 |
| 5 | Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Hit paper breakdown → | 2014 | 774 |
| 6 | Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 Hit paper breakdown → | 2005 | 652 |
| 7 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 614 |
| 8 | Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Hit paper breakdown → | 2012 | 432 |
| 9 | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 400 |
| 10 | 2012 | 368 | |
| 11 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 321 |
| 12 | 2019 | 319 | |
| 13 | 2013 | 308 | |
| 14 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Hit paper breakdown → | 2021 | 273 |
| 15 | 2010 | 270 | |
| 16 | Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer Hit paper breakdown → | 2022 | 180 |
| 17 | 2010 | 161 | |
| 18 | 2014 | 158 | |
| 19 | 2022 | 149 | |
| 20 | Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes Hit paper breakdown → | 2024 | 147 |
About Priya Rastogi
Priya Rastogi is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Genetics and Molecular Biology, having authored 114 papers that have together received 16.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (44 papers), HER2/EGFR in Cancer Research (37 papers), Advanced Breast Cancer Therapies (24 papers), Cancer Treatment and Pharmacology (14 papers), Metabolism, Diabetes, and Cancer (8 papers), PARP inhibition in cancer therapy (6 papers), Estrogen and related hormone effects (5 papers) and Cancer Risks and Factors (5 papers). The work is most often cited by research in Cancer Research (7.1k citations), Oncology (7.8k citations), Pulmonary and Respiratory Medicine (2.8k citations), Radiology, Nuclear Medicine and Imaging (1.8k citations) and Pathology and Forensic Medicine (1.2k citations). Priya Rastogi has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Charles Edward Geyer Jr, Norman Wolmark, Eleftherios P. Mamounas, Sandra M. Swain, Victor G. Vogel, André Robidoux, Louis Fehrenbacher, Soonmyung Paik, Richard G. Margolese and Harry D. Bear. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, JNCI Journal of the National Cancer Institute, Breast Cancer Research and Treatment and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.